GLA
TGTX icon

Great Lakes Advisors’s TG Therapeutics TGTX Stock Holding History

Great Lakes Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
20,124
+2,185
+12% +$89.4K 0.01% 512
2026
Q1 		$596K Hold
17,939
– – ﹤0.01% 573
2025
Q4 		$535K Buy
17,939
+2,043
+13% +$66.7K ﹤0.01% 598
2025
Q3 		$574K Buy
15,896
+3,890
+32% +$128K ﹤0.01% 594
2025
Q2 		$432K Buy
12,006
+1,826
+18% +$68K ﹤0.01% 638
2025
Q1 		$401K Buy
+10,180
New +$343K ﹤0.01% 644

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Great Lakes Advisors's TGTX Position: Q2 2026 in Review

Great Lakes Advisors increased its TG Therapeutics (TGTX) stake by 12% in Q2 2026, buying an estimated $89.4K and bringing the position to 20,124 shares worth $1.11M. The position accounts for 0.01% of the portfolio, ranked #512.

Great Lakes Advisors first reported a position in TGTX in Q1 2025 and has held it in 6 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Great Lakes Advisors held 20,124 shares of TG Therapeutics worth $1.11M as of Q2 2026.
  • Great Lakes Advisors bought 2,185 TG Therapeutics shares in Q2 2026, an estimated $89.4K.
  • TG Therapeutics made up 0.01% of Great Lakes Advisors's portfolio in Q2 2026, its #512 holding.
  • Great Lakes Advisors first reported a position in TG Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.